Phase I Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Couple T-Cell Receptors (CD16V-41BB-CD35), in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma
Research Grant
Administered By
Duke Cancer Institute
Awarded By
Unum Therapeutics Inc.
Start Date
December 5, 2016
End Date
March 16, 2021
Administered By
Duke Cancer Institute
Awarded By
Unum Therapeutics Inc.
Start Date
December 5, 2016
End Date
March 16, 2021